Novo Nordisk (NOV) Stock Forecast & Price Target

690 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOV Analyst Ratings

Hold

1 Buy

12 Hold

1 Sell

Based on 14 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOV Stock 12 Month Forecast

Average Price Target

€39.69

▼(-7.70% Downside)

Based on 14 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €39.69 with a high forecast of €46.82 and a low forecast of €26.75. The average price target represents a -7.70% change from the last price of €43.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"€25","31":"€31","37":"€37","43":"€43","49":"€49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.81775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.68704653846154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€39.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.753,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,31,37,43,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.9,41.35521153846154,41.81042307692307,42.26563461538461,42.72084615384615,43.176057692307694,43.63126923076923,44.08648076923077,44.54169230769231,44.99690384615384,45.45211538461538,45.90732692307692,46.362538461538456,{"y":46.81775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.9,40.806695887573966,40.713391775147926,40.62008766272189,40.52678355029585,40.43347943786982,40.34017532544379,40.24687121301775,40.153567100591715,40.06026298816568,39.96695887573964,39.87365476331361,39.78035065088757,{"y":39.68704653846154,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.9,39.81176923076923,38.72353846153846,37.63530769230769,36.54707692307692,35.45884615384615,34.370615384615384,33.282384615384615,32.194153846153846,31.105923076923077,30.017692307692307,28.92946153846154,27.84123076923077,{"y":26.753,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.796,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.289,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.401,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.735,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.572,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.285,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.701,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.21,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.15,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":43.29,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":40.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€46.82

Average Price Target€39.69

Lowest Price Target€26.75

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kerry Holford

Berenberg Bank

€43.47→€40.8

Hold

-5.12%

Downside

Downgraded

08/12/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These NA Companies: Novo Nordisk (LSE: GB:0QIU), Symrise (LSE: GB:0G6T) and Fraport AG Frankfurt Airport Services Worldwide (LSE: GB:0O1R)

Graham Parry

Citi

€44.14→€41.47

Hold

-3.56%

Downside

Reiterated

08/07/26

Novo Nordisk price target lowered to DKK 310 from DKK 330 at CitiNovo Nordisk price target lowered to DKK 310 from DKK 330 at Citi

Emmanuel Papadakis

Deutsche Bank

€38.79

Hold

-9.79%

Downside

Reiterated

08/06/26

Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)

James Gordon CFA

Barclays

€40.13→€41.47

Hold

-3.56%

Downside

Reiterated

08/06/26

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

€46.82

Hold

8.88%

Upside

Reiterated

08/06/26

Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

€41.47→€38.12

Hold

-11.34%

Downside

Reiterated

08/06/26

Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs

Matthew Weston

UBS

€44.41

Hold

3.28%

Upside

Reiterated

08/05/26

UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)

Justin Smith

Bernstein

€26.75

Sell

-37.78%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

€38.12

Hold

-11.34%

Downside

Reiterated

08/04/26

Novo Nordisk (0QIU) Receives a Hold from Jefferies

Richard Vosser

J.P. Morgan

€33.44

Hold

-22.23%

Downside

Reiterated

07/31/26

J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)

Rajesh Kumar

HSBC

€37.45→€40.13

Hold

-6.68%

Downside

Reiterated

07/06/26

Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBCNovo Nordisk price target raised to DKK 300 from DKK 280 at HSBC

Martin Brenoe

Nordea Markets

€46.82

Buy

8.88%

Upside

Upgraded

06/19/26

Novo Nordisk upgraded to Buy from Hold at NordeaNovo Nordisk upgraded to Buy from Hold at Nordea

David Evans

Kepler Capital

€37.45→€38.79

Hold

-9.79%

Downside

Reiterated

05/22/26

Kepler Capital Keeps Their Hold Rating on Novo Nordisk (0QIU)

Thibault Boutherin

Morgan Stanley

€33.44

Hold

-22.23%

Downside

Reiterated

05/07/26

Morgan Stanley Remains a Hold on Novo Nordisk (0QIU)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kerry Holford

Berenberg Bank

€43.47→€40.8

Hold

-5.12%

Downside

Downgraded

08/12/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These NA Companies: Novo Nordisk (LSE: GB:0QIU), Symrise (LSE: GB:0G6T) and Fraport AG Frankfurt Airport Services Worldwide (LSE: GB:0O1R)

Graham Parry

Citi

€44.14→€41.47

Hold

-3.56%

Downside

Reiterated

08/07/26

Novo Nordisk price target lowered to DKK 310 from DKK 330 at CitiNovo Nordisk price target lowered to DKK 310 from DKK 330 at Citi

Emmanuel Papadakis

Deutsche Bank

€38.79

Hold

-9.79%

Downside

Reiterated

08/06/26

Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)

James Gordon CFA

Barclays

€40.13→€41.47

Hold

-3.56%

Downside

Reiterated

08/06/26

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

€46.82

Hold

8.88%

Upside

Reiterated

08/06/26

Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

€41.47→€38.12

Hold

-11.34%

Downside

Reiterated

08/06/26

Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs

Matthew Weston

UBS

€44.41

Hold

3.28%

Upside

Reiterated

08/05/26

UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)

Justin Smith

Bernstein

€26.75

Sell

-37.78%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

€38.12

Hold

-11.34%

Downside

Reiterated

08/04/26

Novo Nordisk (0QIU) Receives a Hold from Jefferies

Richard Vosser

J.P. Morgan

€33.44

Hold

-22.23%

Downside

Reiterated

07/31/26

J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)

Rajesh Kumar

HSBC

€37.45→€40.13

Hold

-6.68%

Downside

Reiterated

07/06/26

Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBCNovo Nordisk price target raised to DKK 300 from DKK 280 at HSBC

Martin Brenoe

Nordea Markets

€46.82

Buy

8.88%

Upside

Upgraded

06/19/26

Novo Nordisk upgraded to Buy from Hold at NordeaNovo Nordisk upgraded to Buy from Hold at Nordea

David Evans

Kepler Capital

€37.45→€38.79

Hold

-9.79%

Downside

Reiterated

05/22/26

Kepler Capital Keeps Their Hold Rating on Novo Nordisk (0QIU)

Thibault Boutherin

Morgan Stanley

€33.44

Hold

-22.23%

Downside

Reiterated

05/07/26

Morgan Stanley Remains a Hold on Novo Nordisk (0QIU)

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months

Justin SmithBernstein

Success Rate

1/3 ratings generated profit

Average Return

-8.87%

Copying Justin Smith's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -8.87% per trade.

1 Year

Justin SmithBernstein

Success Rate

1/3 ratings generated profit

Average Return

-11.63%

Copying Justin Smith's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.63% per trade.

2 Years

Justin SmithBernstein

Success Rate

1/3 ratings generated profit

Average Return

-11.63%

Copying Justin Smith's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -11.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOV Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOV has received 2 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. NOV average Analyst price target in the past 3 months is 39.69.

Each month's total comprises the sum of three months' worth of ratings.

NOV Financial Forecast

NOV Earnings Forecast

Next quarter’s earnings estimate for NOV is €0.66 with a range of €0.59 to €0.78. The previous quarter’s EPS was €0.83. NOV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.70% of the time in the same period. In the last calendar year NOV has Performed in-line its overall industry.

NOV Sales Forecast

Next quarter’s sales forecast for NOV is €9.74B with a range of €9.41B to €10.19B. The previous quarter’s sales results were €10.50B. NOV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.46% of the time in the same period. In the last calendar year NOV has Performed in-line its overall industry.

NOV Stock Forecast FAQ

What is DE:NOV’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 39.69.

What is DE:NOV’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:NOV, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold, which is based on 1 buy ratings, 12 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 39.69. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €46.82 ,and the lowest forecast is €26.75. The average share price target represents -7.70% Decrease from the current price of €43.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of DE:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (NOV) Stock Forecast & Price Target

NOV Analyst Ratings

NOV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NOV Analyst Recommendation Trends

NOV Financial Forecast

NOV Earnings Forecast

NOV Sales Forecast

NOV Stock Forecast FAQ

Detailed List of Analyst Forecasts